priors.science/reviews/alk-and-ros1-inhibitors

ALK and ROS1 Inhibitors

The current evidence on 23 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

23claims tracked
103primary papers reviewed
4 May 2026latest evidence review
Weeklyre-scored against new papers
7 Established · 15 Likely · 1 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StableNext-generation ALK tyrosine kinase inhibitors vs crizotinib progression-free survivalAlkinlEstablished94%8
StableNext-generation ALK tyrosine kinase inhibitors vs crizotinib for brain metastasesCNSEstablished91%5
StableImmune checkpoint inhibitor monotherapy in ALK-positive non-small cell lung cancerIciEstablished89%4
StableCrizotinib objective response rate in ROS1-positive non-small cell lung cancerRos1Established89%6
StableLorlatinib hyperlipidemia vs second-generation inhibitorsSafetyEstablished89%7
StableCrizotinib in ALK-positive inflammatory myofibroblastic tumourEmergingEstablished86%4
StableALK kinase domain mutations and second-generation resistanceResistEstablished86%4
StableLorlatinib central nervous system adverse effectsSafetyLikely84%4
StableAdjuvant alectinib disease-free survival in ALK-positive non-small cell lung cancerAlkinlLikely82%5
StableRNA-based vs DNA-based next-generation sequencing for fusionsBiomarkLikely82%5
StableSequential immune checkpoint inhibitor then ALK tyrosine kinase inhibitor toxicitySafetyLikely82%4
StableLiquid biopsy sensitivity for fusionsBiomarkLikely81%5
StableALK inhibitors in anaplastic large cell lymphomaEmergingLikely81%2
StableALK-positive non-small cell lung cancer immunosuppressive tumour microenvironmentIciLikely77%4
StableCompound ALK mutations and lorlatinib resistanceResistLikely77%3
StableRepotrectinib progression-free survival in tyrosine kinase inhibitor-naive ROS1-positive diseaseRos1Likely77%4
StableLorlatinib superior intracranial controlCNSLikely76%4
StableOff-target bypass in ALK tyrosine kinase inhibitor resistanceResistLikely76%4
StableRepotrectinib after crizotinib in ROS1-positive diseaseRos1Likely75%4
StableLorlatinib progression-free survival advantage over alectinibAlkinlLikely74%5
StableNext-generation ALK tyrosine kinase inhibitors in inflammatory myofibroblastic tumour after crizotinibEmergingLikely70%3
StableALK tyrosine kinase inhibitor plus immune checkpoint inhibitor combinationIciLikely68%5
StableEML4-ALK variant 3 and resistance mutation riskResistUncertain59%4
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic